Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHV370 in Sjögren's syndrome and mixed connective tissue disease
2020-004937-19Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Sjögren's syndrome and mixed connective tissue disease (MCTD) comparing MHV370 with Placebo (2 arms). Primary endpoint: Change from baseline in ESSDAI at Week 24 in Sjögren's syndrome participants. Started Jul 2021; status: completed.
02
Drugs
MHV370
03
Conditions
Sjögren's syndromemixed connective tissue disease (MCTD)
Beyond the preview
Go deeper on 2020-004937-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004937-19.